# US 2010/0168119 A1 · Compositions and methods for minimizing or reducing agonist-induced desensitization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168119 A1
- Document ID: US20100168119A1
- Status: Published application
- Kind: A1
- Application number: 12/603,235
- Filed: 2009-10-21
- Published: 2010-07-01
- Earliest claimed: 2008-11-05
- Assignees: Pharmorx Inc.
- Inventors: David M. Bear; Robert M. Kessler
- Web page: https://patentgrep.com/patent/US20100168119A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/428: condensed with carbocyclic rings
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions are provided for preventing or reversing loss of the therapeutic effect of a drug, where the loss is associated with the repeated administration of the drug to a patient. The method includes administering to the patient a dopamine receptor agonist or partial agonist or a drug that increases the extracellular level of dopamine by enhancing release of dopamine, decreasing the removal of dopamine from the extracellular space, enhancing the synthesis of dopamine within the brain, or decreasing metabolic degradation of dopamine; and also administering to the patient an opioid receptor antagonist in an ultra-low dose amount, wherein the ultra-low dose amount is effective to prevent or reverse loss of therapeutic effects associated with the repeated administration of the drug to the patient. The methods are useful for various treatments, including treating Parkinson's Disease, Restless Leg Syndrome, depression, schizophrenia, psychostimulant drug abuse, or attention deficit disorder.

## Claims

### Claim 1

A method for preventing or reversing loss of the therapeutic effect of a dopamine receptor agonist or partial agonist associated with the repeated administration of the dopamine receptor agonist or partial agonist to a patient comprising:
administering to the patient a dopamine receptor agonist or partial agonist; and
administering to the patient an opioid receptor antagonist in an ultra-low dose amount, wherein the ultra-low dose amount is effective to prevent or reverse loss of a therapeutic effect, the loss being associated with the repeated administration of the dopamine receptor agonist or partial agonist to the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the dopamine receptor agonist or partial agonist is administered in an amount that is therapeutically effective when co-administered with the opioid receptor antagonist in an ultra-low dose amount.

### Claim 3 (depends on 1)

The method of claim 1, wherein the opioid receptor antagonist is selected from the group consisting of naloxone, naltrexone, diprenorphine, etorphine, dihydroetorphine, and combinations thereof

### Claim 4 (depends on 1)

The method of claim 1, wherein the dopamine receptor agonist or partial agonist is selected from the group consisting of pramipexole, ropinirole, bromocriptine, pergolide, preclamol, talipexole, roxindole, rotigotine, SDZ 208-911, SDZ 208-912, bifeprunox, aripiprazole, PD 158771, PD128483, N-propylnorapomorphine, apomorphine, sumanirole, aplindore, BP897, CJB090, RGH237 and combinations thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 1.5 μg/kg.

### Claim 6 (depends on 1)

The method of claim 1, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 150 ng/kg.

### Claim 7 (depends on 1)

The method of claim 1, wherein the ultra-low dose opioid receptor antagonist is administered from a device, a composition, or a combination device/composition, which is separate from a device, a composition, or a combination device/composition for administering the full or partial opioid dopamine agonist.

### Claim 8 (depends on 1)

The method of claim 1, wherein the ultra-low dose opioid receptor antagonist is administered by depot injection at a dose from about 0.01 ng/kg to about 100 μg/kg.

### Claim 9

A method for preventing or reversing loss of the therapeutic effect of a drug associated with the repeated administration of the drug to a patient comprising:
administering to the patient a drug that increases the extracellular level of dopamine by enhancing release of dopamine, decreasing the removal of dopamine from the extracellular space, decreasing metabolic degradation of dopamine, or enhancing the synthesis of dopamine within the brain; and
administering to the patient an opioid receptor antagonist in an ultra-low dose amount, wherein the ultra-low dose amount is effective to prevent or reverse loss of a therapeutic effect, the loss being associated with the repeated administration of the drug to the patient.

### Claim 10 (depends on 9)

The method of claim 9, wherein the drug releases dopamine from the dopamine neuron, blocks the reuptake of dopamine into the dopamine neuron by blocking the dopamine transporter, decreases the metabolic degradation of dopamine in the brain, or increases the synthesis of dopamine, and wherein the drug is administered in a therapeutically effective amount when co-administered with the opioid receptor antagonist in an ultra-low dose amount.

### Claim 11

A pharmaceutical formulation comprising:
a dopamine receptor agonist or partial agonist or a drug that increases the extracellular level of dopamine by enhancing release of dopamine, decreasing the removal of dopamine from the extracellular space, decreasing metabolic degradation of dopamine, or enhancing the synthesis of dopamine within the brain; and
an opioid receptor antagonist in an ultra-low dose amount.

### Claim 12 (depends on 11)

The pharmaceutical formulation of claim 11, wherein the pharmaceutical formulation comprises at least one unit dosage form.

### Claim 13 (depends on 11)

The pharmaceutical formulation of claim 11, which comprises a dopamine receptor agonist or partial agonist, and the dopamine receptor agonist or partial agonist is present in an amount that is therapeutically effective when co-administered with the opioid receptor antagonist in an ultra-low dose amount.

### Claim 14 (depends on 13)

The pharmaceutical formulation of claim 13, wherein the dopamine receptor agonist or partial agonist is selected from the group consisting of pramipexole, ropinirole, bromocriptine, pergolide, preclamol, talipexole, roxindole, rotigotine, SDZ 208-911, SDZ 208-912, bifeprunox, aripiprazole, PD 158771, PD128483, N-propylnorapomorphine, apomorphine, sumanirole, aplindore, BP897, CJB090, RGH237, and combinations thereof.

### Claim 15 (depends on 11)

The pharmaceutical formulation of claim 11, which comprises a drug which increases extracellular dopamine levels and the drug is present in an amount that is therapeutically effective when co-administered with the opioid receptor antagonist in an ultra-low dose amount.

### Claim 16 (depends on 15)

The pharmaceutical formulation of claim 15, wherein the drug comprises L-DOPA, amphetamine, methylphenidate, a monoamine oxidase inhibitor, a catechol-O-methyl transferase inhibitor, buproprion, a serotonin dopamine reuptake inhibitor, a serotonin norepinephrine reuptake inhibitor, a triple uptake inhibitor, a triple reuptake inhibitor, a dopamine reuptake inhibitor, or a combination thereof.

### Claim 17 (depends on 15)

The pharmaceutical formulation of claim 15, wherein the drug comprises sertraline, duloxetine, venlaxafin, desvenlafaxin, JNJ 7925476, tesofensine, DOV216303, atomoxetine, clozapine, ziprasidone, olanzapine, risperidone, quetiapine, phenelzine, tranylcypromine, selegiline, rasagiline, tolcapone, or a combination thereof.

### Claim 18 (depends on 11)

The pharmaceutical formulation of claim 11, wherein the opioid receptor antagonist is selected from the group consisting of naloxone, naltrexone, diprenorphine, etorphine, dihydroetorphine, and combinations thereof.

### Claim 19 (depends on 11)

The pharmaceutical formulation of claim 11, wherein the dopamine receptor agonist or partial agonist, the opioid receptor antagonist, or both, are in an oral dosage form.

### Claim 20 (depends on 11)

The pharmaceutical formulation of claim 11, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 1.5 μg/kg.

### Claim 21 (depends on 11)

The pharmaceutical formulation of claim 11, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 150 ng/kg.

### Claim 22 (depends on 11)

The pharmaceutical formulation of claim 11, wherein the opioid receptor antagonist is selected from the group consisting of naloxone, naltrexone, diprenorphine, etorphine, dihydroetorphine, and combinations thereof, and wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 1.5 μg/kg.

### Claim 23 (depends on 22)

The pharmaceutical formulation of claim 22, which comprises a dopamine receptor agonist or partial agonist, and the dopamine receptor agonist or partial agonist is selected from the group consisting of pramipexole, ropinirole, bromocriptine, pergolide, preclamol, talipexole, roxindole, rotigotine, SDZ 208-911, SDZ 208-912, bifeprunox, aripiprazole, PD 158771, PD128483, N-propylnorapomorphine, apomorphine, sumanirole, aplindore, BP897, CJB090, RGH237, and combinations thereof.

### Claim 24

A method for treating Restless Leg Syndrome, Parkinson's Disease, or another dopamine-related movement disorder in a patient comprising:
administering to the patient a dopamine receptor agonist or partial agonist; and
administering to the patient an opioid receptor antagonist in an ultra-low dose amount,
wherein the dopamine receptor agonist or partial agonist is administered in an amount that is therapeutically effective when co-administered with the opioid receptor antagonist in an ultra-low dose amount.

### Claim 25 (depends on 24)

The method of claim 24, wherein the opioid receptor antagonist is selected from the group consisting of naloxone, naltrexone, diprenorphine, etorphine, dihydroetorphine, and combinations thereof.

### Claim 26 (depends on 24)

The method of claim 24, wherein the dopamine receptor agonist or partial agonist is selected from the group consisting of pramipexole, ropinirole, bromocriptine, pergolide, preclamol, talipexole, roxindole, rotigotine, SDZ 208-911, SDZ 208-912, bifeprunox, aripiprazole, PD 158771, PD128483, N-propylnorapomorphine, apomorphine, sumanirole, aplindore, BP897, CJB090, RGH237, and combinations thereof.

### Claim 27 (depends on 24)

The method of claim 24, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 1.5 μg/kg.

### Claim 28 (depends on 24)

The method of claim 24, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 150 ng/kg.

### Claim 29

A method for treating Restless Leg Syndrome (RLS) in a patient comprising:
administering to the patient a dopamine receptor agonist or partial agonist; and
administering to the patient an opioid receptor antagonist in an ultra-low dose amount.

### Claim 30 (depends on 29)

The method of claim 29, wherein the opioid receptor antagonist is selected from the group consisting of naloxone, naltrexone, diprenorphine, etorphine, dihydroetorphine, and combinations thereof.

### Claim 31 (depends on 29)

The method of claim 29, wherein the dopamine receptor agonist or partial agonist is selected from the group consisting of pramipexole, ropinirole, bromocriptine, pergolide, preclamol, talipexole, roxindole, rotigotine, SDZ 208-911, SDZ 208-912, bifeprunox, aripiprazole, PD 158771, PD128483, N-propylnorapomorphine, apomorphine, sumanirole, aplindore, BP897, CJB090, RGH237, and combinations thereof.

### Claim 32 (depends on 29)

The method of claim 29, wherein the dopamine receptor agonist or partial agonist comprises pramiprexole or ropinirole.

### Claim 33 (depends on 29)

The method of claim 29, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 1.5 μg/kg.

### Claim 34 (depends on 29)

The method of claim 29, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 150 ng/kg.

### Claim 35

A method for treating Parkinson's Disease in a patient comprising:
administering to the patient a dopamine receptor agonist or partial agonist, levodopa, a monoamine oxidase inhibitor, a catechol-O-methyl transferase inhibitor, or a combination thereof; and
administering to the patient an opioid receptor antagonist in a ultra-low dose amount.

### Claim 36 (depends on 35)

The method of claim 35, wherein the opioid receptor antagonist is selected from the group consisting of naloxone, naltrexone, diprenorphine, etorphine, dihydroetorphine, and combinations thereof.

### Claim 37 (depends on 35)

The method of claim 35, wherein the dopamine agonist or partial agonist is selected from the group consisting of pramipexole, ropinirole, bromocriptine, pergolide, preclamol, talipexole, roxindole, rotigotine, SDZ 208-911, SDZ 208-912, bifeprunox, aripiprazole, PD 158771, PD128483, N-propylnorapomorphine, apomorphine, sumanirole, aplindore, BP897, CJB090, RGH237, and combinations thereof.

### Claim 38 (depends on 35)

The method of claim 35, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 1.5 μg/kg.

### Claim 39 (depends on 35)

The method of claim 35, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 150 ng/kg.

### Claim 40

A method for treating depression in a patient comprising:
administering to the patient a therapeutically effective amount of a dopamine agonist, a dopamine partial agonist, a dopamine reuptake inhibitor, a monoamine oxidase inhibitor, a dopamine releasing drug, a selective serotonin dopamine reuptake inhibitor, a serotonin-norepinephrine reuptake inhibitor, or a serotonin-norepinephrine-dopamine reuptake inhibitor;
administering to the patient an opioid receptor antagonist in a ultra-low dose amount effective to prevent or reduce receptor desensitization in dopamine augmentation.

### Claim 41 (depends on 40)

The method of claim 40, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 1.5 μg/kg.

### Claim 42 (depends on 40)

The method of claim 40, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 150 ng/kg.

### Claim 43

A method for treating schizophrenia in a patient comprising:
administering to the patient a therapeutically effective amount of a partial dopamine agonist or of a drug increasing extracellular dopamine levels; and
administering to the patient an opioid receptor antagonist in a ultra-low dose amount effective to prevent or reduce receptor desensitization in dopamine augmentation.

### Claim 44 (depends on 43)

The method of claim 43, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 1.5 μg/kg.

### Claim 45 (depends on 43)

The method of claim 43, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 150 ng/kg.

### Claim 46

A method for treating psychostimulant abuse in a patient comprising:
administering to the patient a therapeutically effective amount of a dopamine D2 and/or D3 agonist or partial agonist, a dopamine reuptake inhibitor, or a dopamine releasing drug; and
administering to the patient an opioid receptor antagonist in an ultra-low dose amount effective to prevent or reduce receptor desensitization in dopamine augmentation.

### Claim 47 (depends on 46)

The method of claim 46, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 1.5 μg/kg.

### Claim 48 (depends on 46)

The method of claim 46, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 150 ng/kg.

### Claim 49

A method for treating attention deficit hyperactivity disorder (ADHD) in a patient comprising:
administering to the patient a therapeutically effective amount of a drug that increases extracellular dopamine levels; and
administering to the patient an opioid receptor antagonist in an ultra-low dose amount effective for receptor stabilization.

### Claim 50 (depends on 49)

The method of claim 49, wherein the opioid receptor antagonist is selected from the group consisting of naloxone, naltrexone, diprenorphine, etorphine, dihydroetorphine, and combinations thereof.

### Claim 51 (depends on 49)

The method of claim 49, wherein the drug that increases extracellular dopamine levels is selected from methylphenidate formulations, amphetamine formulations, or norepinephrine transporter inhibitors.

### Claim 52 (depends on 49)

The method of claim 49, wherein the norepinephrine dopamine transporter inhibitor comprises atomoxetine.

### Claim 53 (depends on 49)

The method of claim 49, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 1.5 μg/kg.

### Claim 54 (depends on 49)

The method of claim 49, wherein the ultra-low dose amount of the opioid receptor antagonist is between about 0.01 ng/kg and about 150 ng/kg.

### Claim 55

A method for treating a dopamine deficiency disease or condition in a patient comprising:
administering to the patient a therapeutically effective amount of a dopamine D2 and/or D3 receptor agonist or partial agonist; and
administering to the patient an opioid receptor antagonist in an ultra-low dose amount effective to prevent or reverse loss of therapeutic effects after repeated administration of the dopamine D2 and/or D3 receptor agonist or partial agonist.

### Claim 56 (depends on 55)

The method of claim 55, wherein the dopamine deficiency disease or condition is selected from the group consisting of Parkinson's Disease, Restless Leg Syndrome, depression, schizophrenia, attention deficit disorder, and psychostimulant abuse.

### Claim 57 (depends on 55)

The method of claim 55, wherein the opioid receptor antagonist is selected from the group consisting of naloxone, naltrexone, diprenorphine, etorphine, dihydroetorphine, and combinations thereof.

### Claim 58 (depends on 55)

The method of claim 55, wherein the dopamine D2 and/or D3 receptor agonist or partial agonist and/or the opioid receptor antagonist is/are administered via a depot injection, a topical cream or gel, a transdermal device, or a pump.

### Claim 59

A method for the treatment of pituitary adenomas in a patient, comprising:
administering to the patient a therapeutically effective amount of a dopamine D2 agonist; and
administering to the patient an opioid receptor antagonist in an ultra-low dose amount effective to reduce or prevent desensitization of dopamine D2 receptors.

### Claim 60 (depends on 59)

The method of claim 59, wherein the dopamine D2 agonist comprises bromocriptine.

### Claim 61 (depends on 59)

The method of claim 59, wherein the opioid receptor antagonist in an ultra-low dose amount comprises naltrexone orally administered in a daily dose of 0.01 ng/kg to 1.5 μg/kg.

### Claim 62 (depends on 54)

The method of claim 54, wherein the opioid receptor antagonist in an ultra-low dose amount comprises naltrexone administered by depot njection of between about 0.01 ng/kg and about 100 μg/kg.

### Claim 63

A method of treatment comprising:
identifying a patient having a condition selected from the group consisting of Parkinson's Disease, Restless Leg Syndrome, depression, schizophrenia, psychostimulant drug abuse, and attention deficit disorder; and
administering to the patient an opioid receptor antagonist in an ultra-low dose amount in combination with a non-opioid therapeutic agent for the condition.
